Rheumatologist and Physician Salaries for 2018
Medpage Today has published the results of their 2018 Rheumatology Specialty Salaray Survey.
News
TIF1-Ab in Dermatomyositis Linked to Higher Cancer Risk
Several epidemiological studies have reported that a diagnosis of DM or PM may be associated with increased cancer risk. The association appears stronger for DM than PM.
H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis
Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.
Rising Physician Exclusion from Medicare and Medicaid
JAMA Network Open has published that an increasing number of physicians are being excluded from Medicare and other forms of public insurance.
Cryotherapy Never FDA Approved
Another injury related to whole body cryotherapy (WBC) has been reported by practitioners in Philadelphia, serving as yet another warning of WBC's potential to cause serious adverse effects.
RheumNow Podcast – Vasculitis and Strange Bedfellows (12.14.18)
Dr. Jack Cush reviews the news from the past week on RheumNow.com.
CDC Top 15 Most Common Opioid Overdose Drugs
The Dec. 12 issue of the National Vital Statistics Reports from the U.S. Centers for Disease Control and Prevention reports that the most commonly abused drugs causing drug overdose deaths (between 2011-2016) include fentanyl, heroin, oxycodone, and cocaine.
Psoriatic Arthritis Does Not Add to Pregnancy Problems
When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.
No End in Sight for the Shingrix Vaccine Shortage
There is a national shortage of a new shingles vaccine, Shingrix, which is a problem for those who want to start the vaccine and those seeking to receive their second and final injection.
IL-23 Outduels IL-17 Inhibition in Psoriasis
Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.
CV Risks Similar in Systemic Sclerosis and Rheumatoid Arthritis
Interactions between disease-related inflammatory processes and the development of several morbidities have been well-studied in RA, particularly heart disease. This is not the case for the often-lethal SSc (estimated standardized mortality ratio between 2.5 and 4.0).
